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Background. Vascular damage is recognized as a diagnostic landmark in systemic sclerosis (SSc), both in its limited and diffuse
subtypes. Early detection at a subclinical stage with transthoracic echocardiography (TTE) and carotid femoral pulse wave velocity
(cfPWV)may be helpful in therapeutic planning andmanagement.Aim of the Study.&e aim of the study was to evaluate presence
of subclinical cardiovascular damage in patients with limited and diffuse SSc in comparison with a cohort of healthy individuals.
Methods. Consecutive patients with limited and diffuse SSc underwent complete TTE and cfPWV and a complete review of clinical
data. As controls, 23 healthy subjects with similar hemodynamic profiles were selected. Results. 41 patients (35 female, aged 56.9
years), 21 with diffuse and 20 with limited SSc, were recruited. Past medical history, cardiovascular risk factors, gender dis-
tribution, and disease duration were similar in the two groups as well as TTE parameters and hemodynamic indexes—cfPWV (6.5
[6–6.8] vs. 7.0 [6.2–8.5], p � 0.24) and augmentation index (145.6± 14.2 vs. 149± 20.6, p � 0.52). Patients with limited SSc were 10
years older than patients with diffuse SSc. In the multiple regression analysis, only age (p � 0.0154) and disease duration
(p � 0.0467) resulted as the significant determinant of cfPWV. When compared to healthy controls, no significant difference
emerged in TTE or hemodynamic indexes. Conclusion. In SSc, cfPWV increases with age, with no additional impact of pathology
or subtype. Vascular damage in the SSc population is not accurately reflected in increased arterial stiffness, as evaluated with
cfPWV, or classically defined echocardiographic findings of organ damage (i.e., left ventricular concentric remodelling and
increased filling pressures).
1. Background
Systemic sclerosis (SSc) is a chronic and progressive con-
nective tissue disease arising as a consequence of altered
immunologic processes, with vascular injury, inflammation,
and fibrosis of the skin and different internal organs [1]. A
“limited” and a “diffuse” subtype of the disease are recog-
nized and differentiated on the basis of different autoanti-
bodies pattern and clinically distinct visceral and cutaneous
involvement, with the diffuse form showing a more severe
phenotype [2]. Microvascular involvement is one of the
hallmarks of the disease, but the damage can occur at every
level of the vascular tree [3].
Carotid-femoral pulse wave velocity (cfPWV), the gold
standard for noninvasive evaluation of arterial stiffness [4],
has demonstrated a specific role in cardiovascular risk
stratification independently of other well-known risk factors
[5, 6].
cfPWV has been shown to be higher in SSc patients than
in healthy, age-matched controls in some [7–9] but not all
[9, 10] previous works. &e specific role of SSc in promoting
arterial stiffening is therefore still unclear, as well as impact
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of SSc subtypes on macrovascular damage as assessed
specifically by cfPWV.
&e aim of the study was to evaluate the presence of
subclinical cardiac organ damage and arterial stiffness, as a
landmark of macrovascular damage, with the current gold
standard represented by transthoracic echocardiography
and cfPWV in patients with SSc, focusing in particular on
differences between limited and diffuse SSc.
2. Methods
2.1. Patients. Consecutive patients referred to the Rheu-
matology Department of “Città della Salute e della Scienza,”
University Hospital in Turin (Italy), were recruited. All
patients met the ACR–Euler criteria for SSc diagnosis and
classification [11]. Past medical history, risk factors, and
family history were assessed through a detailed anamnestic
interview. SSc subtype and clinical and serological data were
collected for each patient from their medical records. SSc-
specific data—pulmonary function test, EGDS capillaro-
scopy results, autoantibodies pattern, and renal func-
tion—were retrieved from the EUSTAR (European
Scleroderma Trials and Research group) database for every
patient.
Patients with either limited or diffuse systemic sclerosis
were compared to a well-matched control population
consisting of healthy, normotensive volunteer subjects (no
history of arterial hypertension or antihypertensive treat-
ment, confirmed normal office blood pressure and ABPM
values, and absence of hypertension mediated organ dam-
age), free of cardiovascular diseases (such as coronary artery
disease, valvular heart disease, aortic disease, atrial fibril-
lation, stroke, chronic kidney failure, and diabetes), evalu-
ated at the Hypertension Unit of the same institution. &e
study was approved by the local ethical committee, and all
patients gave their informed consent to participate.
2.2. Cardiovascular Organ Damage Evaluation
2.2.1. Echocardiography. All subjects involved in the study
underwent a complete evaluation of cardiovascular target
organ damage with a complete transthoracic echocardio-
gram (TTE) and with central pressure appraisal and cfPWV
measurement.
A two-dimensional (2D) TTE was performed in all
patients at rest in the left lateral decubitus position, with a
commercially available ultrasound system equipped with a
S5 probe for 2-dimensional and tissue Doppler imaging
acquisition (iE33, Philips Medical System, Andover, Mas-
sachusetts). In brief, left ventricular (LV) mass was calcu-
lated from the end-diastolic LV internal diameter (LVIDd),
interventricular septum (IVS), and inferolateral wall
thickness (ILW) and normalized to body surface area (BSA).
Relative wall thickness (RWT) was calculated as (2∗ILW)/
LVIDd. Patterns of left ventricular geometry were defined
according to the ESH/ESC recommendations. LV hyper-
trophy was defined as LV mass indexed to BSA >95 g/m2 in
women or >115 g/m2 in men. Body surface area (BSA) was
calculated using the DuBois and DuBois formula. LV vol-
umes were assessed through Simpson’s biplane technique
from apical 4- and 2-chamber views and indexed to body
surface area and then used to evaluate LV systolic function
(LV ejection fraction, EF). Offline analysis and measure-
ments were performed in agreement with the last Interna-
tional Guidelines [12], by expert European Association of
Echocardiography-accredited staff.
2.2.2. cfPWV and Ai. In the same day, central pressure
appraisal and cfPWV evaluation were performed following
standardized protocols. In brief, blood pressure and heart
rate were measured three times, at 2min intervals using a
validated automatic oscillometric device (OmronMatsusaka
Co., Ltd., Mie, Japan). &e mean value from these three
measurements was used for further analysis.
cfPWV was measured along the descending thor-
acoabdominal aorta by the foot-to-foot velocity method,
with a dedicated instrument (Sphygmocor system, AtCor
Medical, Sydney, Australia) as previously published and
validated [13]. With this system, pressure waveforms are
obtained with a dedicated transcutaneous transducer ap-
plied sequentially over the common carotid artery and the
femoral artery. &e time delay, or pulse transit time (t, in
seconds), is measured by subtracting the time between ECG-
R wave and proximal (carotid) waveform foot from the time
between ECG-R wave and distal (femoral) waveform foot. In
consideration of the strong heart rate dependence, PWV
values which were obtained with heart rate difference >10%
between carotid and femoral sites were discarded. &e
distance covered by the pulse wave (D, in meters) is sup-
posed to be the surface distance between the carotid and
femoral recording sites. &erefore, it is calculated by mul-
tiplying the surface distance measured between the two
points by a correction factor of 0.8, as previously described
in detail and validated [4, 14].
cfPWV is obtained as D/t. A cfPWV value> 10m/sec
was considered pathologic [15].
&e assessment of the augmentation index and central
pressures was allowed by the estimation of aortic pressure
waveforms, which were obtained through the measurement
of radial artery waveforms, by using a high-fidelity micro-
manometer (SPC-301; Millar Instruments, Houston, Texas,
USA). Radial artery tonometry was performed, and a vali-
dated transfer function (Sphygmocor, AtCor, Sydney,
Australia) was applied in order to calculate aortic pressure
waveforms. &e calibration of central artery pressure was
obtained by using noninvasively recorded brachial blood
pressure as surrogate of radial arterial pressure. &is method
is based on the fact that mean blood pressure remains
constant and diastolic blood pressure does not significantly
change along the artery tree [4]. Augmentation pressure was
defined as the height of the late systolic peak above the
inflection.&e aortic or central augmentation index (Ai) was
calculated as the ratio of the pressure difference between the
“shoulder” of the pressure wave and “peak” systolic pressure
[16].
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2.2.3. Statistical Analysis. &e statistical analysis was per-
formed using R, a free software environment for statistical
computing and graphics (the R-fundation, GNU Free
Software Foundation, Boston, MA, USA) [17]. &e para-
metric distribution of the variables was analyzed using the
Kolmogorov–Smirnov test and residual analysis. Data are
presented as mean± standard deviation (SD), or median (1st
and 3rd quartiles), where appropriate. &e difference be-
tween groups was evaluated with the T-test or a three-way
ANOVA for normally distributed variables. &e Man-
n–Whitney-Wilcoxon test was used for nonnormally dis-
tributed variables, and the χ2 test or Fisher’s exact test was
used when appropriate. Correlations among different var-
iables were performed using Person or Spearman’s test
where appropriate. An alpha-error <0.05 was considered
significant in all analysis.
3. Results
A total of 41 patients (female 35, 85.3%; mean age:
56.9± 13.6 years), 21 with diffuse SSc and 20 with limited SSc
were recruited. Table 1 summarizes anthropometric, clinical,
and anamnestic data of the whole population and of the two
subgroups of patients with limited and diffuse SSc.
3.1.Diffuse vs. Limited SSc. Comparing patients with the two
different subtypes of SSc, it clearly showed a similar back-
ground: past medical history, familiarity, cardiovascular risk
factors, gender distribution, and disease duration were all
similar. However, patients with limited SSc were averagely
10 years older than patients with diffuse SSc (51.7± 12.7 vs.
62.4± 12.5, p � 0.009). Clinical features were as expected
different, with patients with diffuse SSc showing higher
prevalence of pulmonary fibrosis, a trend to poor-
er—although nonstatistically significant—performance on
the 6-minute walking test, worse pulmonary function as
evaluated by FVC, and an higher MRSS.
Echocardiographic parameters (Table 2) describing
potential subclinical cardiac organ damage did not show
significant difference between the two subgroups of patients.
Left ventricular hypertrophy was found only in 4 of the 41
patients—all female—3 of whomwere affected by diffuse SSc
(p for difference� ns). Tissue Doppler parameters evaluating
diastolic function were within normal limit for the majority
of the population and showed no significant difference
between limited and diffuse SSc. &e few patients (n�5) that
showed abnormal Tissue Doppler parameters were all sig-
nificantly older than patients showing no abnormalities.
Indexed left atrial volume was increased in only 5 patients,
again significantly older than the ones showing normal atrial
volume, and again with no significant difference between the
two subgroups. None of the patients had increased pul-
monary pressure values on TTE evaluation.
Patients with limited and systemic SSc also showed
similar arterial stiffness, both in terms of cfPWV (6.5 [6–6.8]
vs. 7.0 [6.2–8.5]m/sec, p � 0.24) and Ai (145.6± 14.2 vs.
149± 20.6, p � 0.52). A total of 4 patients showed increased
(>10m/sec) cfPWV, with no significant difference in
distribution among limited or diffuse form of the disease.
&ese patients were averagely older (73.5 vs. 55.5 years
p � 0.01) but had similar disease duration than the patients
with normal cfPWV (p � 0.27). Dividing patients on the
basis of the presence or absence of classical cardiovascular
risk factors did not lead to significant difference in the
recorded cfPWV, nor cfPWV showed significant difference
when the subanalysis was made on the basis of presence of
clinical manifestation such as acral ulcers, esophageal hy-
potonia, pulmonary fibrosis, or positive finding on capil-
laroscopy (data not shown).
3.2. Regression Analysis. In the regression analysis, cfPWV
showed a good correlation with age (r�0.60, p< 0.001) and a
fair correlation with disease duration (r� 0.36, p � 0.02). As
expected, cfPWV was significantly correlated with both
peripheral (SPB: r�0.51, p< 0.001; DBP: r�0.36, p � 0.02;
MBP: r�0.45, p � 0.003) and central blood pressure values
(cSPB: r 0.49, p � 0.001; cDBP: r�0.37, p � 0.03; cMBP:
r� 0.44, p � 0.003), while Ai did not show significant cor-
relations with any of those variables.
In a multiple regression analysis (Table 3), only age and
disease duration maintained a significant correlation with
cfPWV after correction for SSc subtype and central and
peripheral hemodynamic parameters.
By introducing heart rate and height as independent
variables in the multivariate regression analysis, we have
found that only age maintained a significant correlation with
cfPWV (p � 0.001), while only height was significantly and
inversely correlated with Ai (p � 0.001) (Table 4).
3.3. SSc vs. Controls. Compared to healthy subjects with
well-matched hemodynamic profiles (supplemental table
S1), SSc patients—irrespective of the clinical subset—did not
show a significant increase in arterial stiffness: cfPWV
resulted similar in all three groups (6.5 [6–6.8] vs. 7.0
[6.2–8.5] vs. 6.7 [6.2–8] in diffuse SSc, limited SSc, and
controls, respectively, p � 0.458), and no difference in
cardiac organ damage, as evaluated with echocardiography,
was detected. In a multiple regression analysis mirroring the
one performed in SSc patients only, only age maintained
significant correlation with cfPWV (p � 0.008) after cor-
rection for disease status (patient vs. controls) and central
and peripheral hemodynamic parameters.
4. Discussion
In the present study, we evaluated subclinical cardiovascular
organ damage in SSc, with particular focus on comparing the
two clinical subforms of limited and diffuse SSc, using two
standardized evidence-based technologies, TTE and cfPWV.
Echocardiographic evaluation did not show significant
prevalence of subclinical organ damage in SSc patients nor
significant difference between the subgroups affected by
limited or diffuse SSc. Arterial stiffness evaluated with
cfPWV showed good correlation with disease duration and
patient age. Moreover, cfPWV resulted similar in patients
with limited and diffuse SSc, with the latter group of
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individuals being however, on average, 10 years younger.
Disease duration was equivalent in the two subgroups,
suggesting that in the diffuse form of the disease, macro-
vascular damage as assessed by cfPWV and arterial stiffening
may be accelerated and more pronounced. However, this
hypothesis did not hold true when SSc patients were
compared to a well-matched group of healthy individuals
that showed similar arterial stiffness parameters.
Cardiovascular diseases are highly prevalent in patients
with rheumatic pathologies, such as lupus erythematous and
rheumatoid arthritis, and are among the leading causes of
mortality in this clinical setting [18–20]. Mechanisms for
Table 2: Echocardiographic and hemodynamic parameters of SSc patients.
All Diffuse Limited p
LVmass (gr) 120 [105–152] 141 [105–184] 122 [102–138] 0.48
LVMi(gr/m2) 79.3± 24.8 82.8± 27.7 75.7± 21.5 0.35
EF (%) 64± 4 65± 4 64± 4 0.08
LVH (#) 4 (9.7%) 3 (19%) 1 (5%) 0.33
LAVi (cc/m2) 23.7± 8.1 21.2± 7.3 26.5± 8.4 0.052
Dilated LA, # (%) 5 1 (5%) 4 (20%) 0.16
E/e’ avg 8.4± 2.7 7.9± 2.1 9.0± 3.1 0.22
TR (m/sec) 2.4± 0.35 2.2± 0.5 2.4± 0.2 0.21
pSBP (mmHg) 115± 18.7 113± 13 117± 23 0.5
pDBP (mmHg) 69.3± 8.4 69.7± 7.6 68.8± 9.4 0.73
pMBP (mmHg) 87.4± 10.2 86.1± 8.2 88.9± 11.9 0.39
pAI 88.4 [82.5–99.5] 90 [80.3–95] 93 [82–99] 0.24
cSBP (mmHg) 107.4± 17 105.3± 11.8 109.7± 21.3 0.42
cDBP (mmHg) 70.5± 8.5 71.1± 7.5 70± 9.6 0.66
cMBP (mmHg) 87.5± 10 86.1± 8.2 88.4± 11.7 0.5
cAI 147.3± 17.5 145.6± 14.2 149± 20.6 0.52
CFPWV (m/sec) 6.6[6.1–7.8] 6.5 [6–6.8] 7.0[6.2–8.5] 0.24
CFPWV >10, n (%) 4 (9.7%) 2 (9.5%) 2 (10%) 1
Table 1: Clinical characteristics of the SSc study population.
All Diffuse Limited p
N 41 21 (51.2) 20 (48.8)
Age 56.9± 13.6 51.7± 12.7 62.4± 12.5 0.009#
Female (%) 35 (85.3) 17 (81) 18 (90) 0.66$
Smokers 11 (26.8) 4 7 0.35$
Weight (kg) 62.3± 10.6 64.5± 11.4 59.9± 9.4 0.17#
BMI (kg/m2) 24.4± 3.7 24.9± 3.9 23.8± 3.5 0.35#
SBP (mmHg) 118± 17.3 115.9± 16.2 121.2± 18.3 0.33#
DBP(mmHg) 69.7± 8.6 70.7± 7.7 68.6± 9.5 0.44#
HR (bpm) 75± 9.7 77.2± 9.8 72.9± 9.4 0.16#
Past medical history
Alcohol 8 (19.5) 4 (19) 4 (20) 1$
HTN 11 (26.7) 6 (28.6) 5 (25) 1$
Hx of HTN 26 (63.4) 12 (57.1) 14 (70) 0.5$
Dyslipidemia 8 (19.5) 4(19) 4 (20) 1$
Hx of dyslipidemia 14 (34.1) 7 (33.3) 7 (35) 1$
DM 1 (0.02) 1 (0.05) 0
Hx of DM 12 (29.3) 7 (30) 5 (25) 0.73$
SSc-specific parameters
Disease duration (months) 81 [46; 130] 60 [34–94] 88 [67; 130] 0.13$
Autoantibodies
ANA 39 (95.1) 19 (90.5) 20 (100) 0.48$
Scl70 14 (34.1) 14 (66.7) 0 <0.001$
Anticentromere 20 (48.8) 0 20 (100) <0.001$
Clinical features
Acral ulcers 15 (36.6) 11 (52.4) 4 (20) 0.051$
Pulmonary fibrosis 22 (53.6) 15 7 0.006$
Renal crisis 1 (0.02) 1 (0.05) 0
Hypotonia 31 (83.8) 17 (81) 14 (70) 0.67$
Positive capillaroscopy 22 (54) 15 (71.4) 7 (35) 0.054$
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such a correlation have been identified in accelerated ath-
erosclerosis induced by the chronic inflammation envi-
ronment and autoimmune milieu [3], closely interplaying
with more traditionally recognized cardiovascular risk fac-
tors such as hypertension, dyslipidemia, and aging.
In the specific subset of SSc, available data are scanter.
However, evidence is increasing in indicating SSc patients at
higher cardiovascular risk compared to healthy controls
[21]: the European registry indicated indeed that as much as
26% of mortality in SSc patients is related to cardiovascular
diseases [22].
&e underlying exact pathology has still to be clarified, as
well as optimal approaches to screening strategies that may
grant early identification of patients at increased risk. In this
context, evaluation of subclinical cardiovascular organ
damage may represent a pivotal step in patient management.
Dedicated techniques, developed in other clinical scenarios,
may prove to be a valuable tool. Transthoracic echocardi-
ography able to identify increased left ventricular mass,
indexes of diastolic dysfunction, increased left atrial volume
[23], and cfPWV measurement [12, 23], evaluating arterial
stiffness, are among those.
cfPWV in particular has been recognized as playing a
specific role in cardiovascular risk stratification indepen-
dently of other well-known risk factors [5, 6] in hypertensive
patients. Previous studies using this technique have found
increased cfPWV values in SSc patients [7, 8] compared to
controls, suggesting that arterial stiffness may be part of the
disease’s multifaced vascular damage. &is finding has
however not been univocal [9, 10].
In previous work, even when an averagely higher cfPWV
value was detected in an SSc patient, the actual number of
individuals with pathologically increased arterial stiffness
was very low. Moreover, in none of the previous studies was
detected a “pathological” cfPWV in SSc patients. Using a
cutoff of 9m/sec, Colaci et al. [8] reported increased cfPWV
in older individuals and in patients with prolonged disease
duration, hinting a specific role of SSc in inducing arterial
stiffening. &e used cutoff was however an arbitrary one:
threshold values for defining increased cfPWV have been
previously published in international guidelines and pro-
gressively lowered, from 12 [23] to 10m/sec [24], but no data
have been published on the clinical or prognostic signifi-
cance of “relatively increased” cfPWV. Even if it may be
legitimate to argue that such a threshold has been defined for
hypertensive patients and may thus not be automatically
applicable to different clinical settings, further investigations
are needed in the field before such a conclusion can be
drawn. In the same study, a trend for higher cfPWV in
limited SSc was also found. However, data on patients’ age
were not given, so that the aging factor could not be correctly
weighted. Age- and SSc subtype-specific evaluation was
performed by Timár and colleagues [25] who reported a
greater association with increased cfPWV for limited SSc.
&is finding was not confirmed in the present analysis, in
which cfPWVwas similar in the two subforms of the disease.
However, in the cited study, patients with limited SSc were
significantly older—15 years on average—and this may
account for the higher cfPWV shown. Indeed, cfPWV is
widely recognized to increase with age [26], also in the
specific subset of SSc [9, 10].
In the present study, the finding of a comparable cfPWV
in the two subpopulations despite an average age difference
of 10 years could have been interpreted as an accelerated
stiffening of the arteries occurring in diffuse SSc. However,
the lack of significant differences in hemodynamic and
echocardiographic data, once the SSc population was
compared to healthy individuals, weakened such hypothesis.
Our data, together with contradicting results from critically
reviewed previous studies, point out that traditional tools for
the assessment of cardiovascular organ damage—TTE and
cfPWV evaluation—might not be the ideal choices for SSc
patient risk stratification. Other more specific tools could be
better suited to highlight an involvement that might not be
expressed neither as arteriosclerosis, in terms of stiffening of
the great vessel assessed by cfPWV [10], or classic
Table 3: Multivariate regression analysis of cfPWV in SSc patients.
Variables T value p
Age 2.563 0.0154
BMI 1.237 0.2253





Clinical subtype −0.637 0.5287
F 6.31 (<0.001), adjusted R2 � 0.56
BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood
pressure; MBP: mean blood pressure; cSBP: central systolic blood pressure;
cDBP: central diastolic blood pressure; cfPWV: carotid-femoral pulse wave
velocity.
Table 4: Multivariate regression analysis of Ai in diffuse SSc vs.
limited SSc vs. controls.
Variables T value p
Age −0.263 0.794
Height −3.617 0.001






Clinical subtype −0.486 0.629
SBP: systolic blood pressure; DBP: diastolic blood pressure; MBP: mean
blood pressure; cSBP: central systolic blood pressure; cDBP: central dia-
stolic blood pressure; HR: heart rate; Ai: augmentation index.
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atherosclerosis, in terms of increased intima-media thick-
ness [26]. For example, alteration of flow-mediated vaso-
dilatation has been proved to occur in SSc patients [27, 28]
reflecting endothelial dysfunction, a potential key player in
both microvascular and macrovascular involvement.
4.1. Limitations. &is study shares with other published
works on the topic the relatively—as SSc is a rare dis-
ease—small sample size and the monocentric design. We
acknowledge that the lack of statistical difference between
the study groups (limited SSc vs. diffuse SSc vs. control) does
not automatically imply similarity, especially within a small
population like the one we present here. Indeed, it might be
related to the small sample size, and the study itself might be
underpowered to thoroughly assess the lack of any signifi-
cant differences between SSc patients and controls in terms
of cfPWV and cardiovascular organ damage. However, the
correlation analysis did not show a significant impact of SSc
nor its subtype on cfPWV values, highlighting at the same
time the importance of age in the determination of arterial
stiffness.
Second, in the analyzed population, cfPWV values are
mostly within normal limits, with very few patients showing
pathologically increased cfPWV (i.e., >10m/sec) [24].
However, if this small number may be considered to hamper
our results, it is nevertheless a real picture of the SSc
population, in which increased cfPWV is not indeed very
prevalent, supporting our conclusion.
&ird, we underline the limitations related to the
techniques used in this study to calculate central hemody-
namic parameters, since the method to calibrate central
pressures may introduce some errors, even if previously
validated.
5. Conclusions
Echocardiography is one of the tools used for annual
screening in systemic sclerosis patients, in order to detect
patients at high risk for pulmonary arterial hypertension
(PAH) at early stage. For the diagnosis of PAH, the gold
standard remains right heart catheterization. &e main aim
of our paper was to analyze subclinical cardiovascular organ
damage in SSc patients and to study in depth the potential
role of TTE and cfPWV in cardiovascular risk stratification.
Compared to control, patients affected by SSc did not
present significantly increased subclinical cardiac damage
nor arterial stiffness as evaluated, respectively, with standard
echocardiogram and cfPWV, irrespective of their specific
clinical subtypes. &e two forms of SSc—limited and dif-
fuse—showed hemodynamic and cardiac features that were
similar to those of a well-matched healthy population.
Considering the increasingly growing importance of
cost-effectiveness in patient management, our data suggest
that cfPWV analysis and echocardiogrammay be used in the
subsets of SSc patients with additional classical cardiovas-
cular risk factor, better than routinely applied for risk
stratification of the general SSc population. Efforts in
identifying SSc patients at increased cardiovascular risk




DBP: Diastolic blood pressure
cfPWV: Pulse wave velocity
SBP: Systolic blood pressure
SSc: Systemic sclerosis.
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